

This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|---------------------------|---------------------------|--|---|---|
| Infectious disease | | | | |
| Viral infection | Not applicable | <p>Studies on human rhinovirus (HRV) strains suggest that genetic sequencing could lead to the identification of common therapeutic targets within multiple rhinovirus strains. Sequencing and analyses of 99 known HRV-A and HRV-B serotypes plus an additional 10 patient samples led to the identification of species-specific structures and variations in the 5' untranslated region that may be associated with pathogenic diversity. The next steps could include using the information about viruses to develop better antiviral compounds and vaccines. Biota Holdings Ltd. has BTA798, a rhinovirus vaccine, in Phase I testing.</p> <p>SciBX 2(9); doi:10.1038/scibx.2009.366 Published online March 5, 2009</p> | Patent and licensing status unavailable | <p>Palmenberg, A. <i>et al. Science</i>; published online Feb. 12, 2009; doi:10.1126/science.1165557 Contact: Stephen B. Liggett, University of Maryland School of Medicine, Baltimore, Md. e-mail: sligg001@umaryland.edu</p> |